Sino Biopharmaceutical Announces Key Senior Appointments to Drive Innovation and Globalization Strategy

Date: 28 April 2026

Key Highlights

• Appointment of Dr. Kang Xiaoyan as Chief Medical Officer (CMO):
  Dr. Kang will oversee all global clinical development and collaborations for innovative drugs across all therapeutic areas.
• Appointment of Two New Heads of Clinical Development:
  • Dr. Liu Meng – Head of Clinical Development for Chronic Diseases
  • Dr. Liu Rongjun – Head of Clinical Development for Autoimmune Diseases
• Strengthening of Clinical R&D Structure:
  The Group now has a robust clinical R&D leadership in four major therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia.

Detailed Overview of Executive Appointments

Dr. Kang Xiaoyan – Chief Medical Officer

• Over 25 years of experience in clinical practice and drug R&D.
• Expertise in clinical operations, strategic leadership, and global multi-centre clinical studies.
• Previous Leadership Roles: Held key positions at Bayer, Boehringer Ingelheim, Hengrui Pharmaceuticals, Junshi Biosciences, and Qilu Pharmaceutical.
  • Executive Deputy General Manager of Clinical R&D Centre
  • Chief Medical Officer for Oncology
• Track Record: Led global clinical development and medical strategy for innovative oncology drugs, bispecific antibodies, and small-molecule targeted drugs.
• Academic Credentials: Completed postdoctoral research in immunology at Cornell University Medical College, USA; published widely in high-impact journals.

Dr. Liu Meng – Head of Clinical Development for Chronic Diseases

• PhD and MD in Endocrinology from Fudan University.
• Nearly 20 years’ experience in multinational and leading domestic pharma companies (GSK, Boehringer Ingelheim, Innovent Biologics, Hasten Biopharmaceutical).
• Leadership Experience: Led clinical strategies, regulatory filings, and operations for major chronic disease therapies including metabolism, cardiovascular, respiratory, and oncology.
• Key Achievements: Led clinical development of IBI362 (mazdutide) from Phase I through NDA, with results published in top-tier journals and presented internationally.
• Expertise: Extensive experience in global multi-centre trials, real-world studies, and high-level academic collaborations.

Dr. Liu Rongjun – Head of Clinical Development for Autoimmune Diseases

• PhD in Immunology from Fudan University, with clinical hospital experience.
• Over 15 years in R&D leadership for autoimmune and chronic diseases (rheumatology, dermatology, nephrology).
• Previous Roles: Held positions at Hutchison Whampoa, Reistone Biopharma, Lynk Pharmaceuticals, and most recently, Vice President of Medical Affairs at Createrna Science and Technology.
• Achievements:
  • Led clinical development and registration of several blockbuster drugs.
  • Spearheaded development of ivarmacitinib, China’s first domestically developed JAK inhibitor, achieving multiple market approvals.
  • Supported innovative drugs in obtaining Breakthrough Therapy and Priority Review designations.
  • Hands-on experience from clinical development through regulatory approval in China and the US.

Strategic and Potential Price-Sensitive Implications for Shareholders

• Strengthening of Leadership: The appointment of highly experienced and internationally recognized leaders in clinical development significantly strengthens Sino Biopharmaceutical’s capabilities in innovation, R&D, and global collaboration.
• Acceleration of Pipeline Development: The new leadership is expected to drive faster and more effective advancement of innovative drug candidates, potentially leading to earlier approvals and market entries.
• Globalization and Innovation: The reinforced clinical R&D structure will support the Group’s globalization strategy, positioning it to compete more effectively in both domestic and international markets.
• Potential Share Price Impact: The market may interpret these appointments as a strong commitment to innovation and global expansion, which could positively influence investor sentiment and share price, especially as the company aims to expedite the commercialization of high-potential drugs.

Board Composition

As of the announcement date, the Board consists of six executive directors and five independent non-executive directors, ensuring a strong governance structure.

Conclusion

The strategic appointment of these seasoned professionals marks a significant milestone in Sino Biopharmaceutical’s ambition to become a global leader in innovative pharmaceuticals. Shareholders should closely monitor progress on the company’s clinical pipeline and regulatory milestones, as successful execution under this new leadership team could drive substantial value creation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own due diligence and consult professional advisers before making any investment decisions. The information herein is based on the company’s official announcement and may be subject to change.

View SBP GROUP Historical chart here